THE GEORGE INSTITUTE FOR GLOBAL HEALTH
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
88
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (80 trials with phase data)• Click on a phase to view related trials
Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT): Effect of intensive blood pressure lowering treatment provided by a Triple Pill strategy on the time to first occurrence of recurrent stroke in patients with a history of acute stroke due to intracerebral haemorrhage.
- Conditions
- Stroke caused by Intracerebral Hemorrhage (ICH), Hypertension
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- The George Institute for Global Health
- Registration Number
- SLCTR/2017/030
News
FDA Approves First Triple-Combination Hypertension Drug WIDAPLIK for Initial Treatment
The FDA has approved WIDAPLIK (telmisartan, amlodipine, and indapamide), marking the first and only triple-combination medication approved for initial hypertension treatment in adults.
ADVANCE Trial Analysis: Intensive Glucose Control Benefits Type 2 Diabetes Patients Regardless of Disease Onset Age
Post-hoc analysis of ADVANCE trial reveals intensive glucose lowering reduced vascular events risk by 10% and cardiovascular death risk by 12% in type 2 diabetes patients.
Triple-Combination Pill GMRx2 Shows Promise in Revolutionizing Hypertension Treatment
A Phase III clinical trial demonstrated that GMRx2, a triple combination pill, is significantly more effective than dual combinations in controlling blood pressure.
GLP-1 Receptor Agonists Show Promise in Protecting Kidney Health
• A meta-analysis of 11 clinical trials reveals that GLP-1 receptor agonists significantly reduce the risk of kidney failure and worsening kidney function. • The study demonstrates a 16% reduction in kidney failure and a 22% reduction in the worsening of kidney function among patients treated with GLP-1s. • GLP-1 receptor agonists also showed a 14% reduction in cardiovascular events and a 13% reduction in all-cause mortality. • Researchers suggest GLP-1s could play a key role in kidney and heart-protective treatments for individuals with type 2 diabetes, obesity, or chronic kidney disease.